Baili Tianheng (688506.SH): Cumulatively repurchased 863,000 shares of the company's stock

Gelonghui, July 8 — BeiLi TianHeng (688506.SH) announced that, as of the date of this announcement, the company has cumulatively repurchased 863,000 of its shares via centralized bidding transactions through the Shanghai Stock Exchange trading system, representing 0.21% of the company's total share capital. The highest repurchase price was RMB 314.95 per share, and the lowest was RMB 201.02 per share, with a total amount paid of RMB 1,999.453 million (excluding stamp duty, brokerage commissions, and other transaction fees). The current share repurchase program has been fully implemented.

Gelonghui FinanceJul 8 19:47

Pulling back after a sharp short-term rally? A-share innovative drug stocks collectively retreated, with Anglikang and Kelun Pharmaceutical down more than 8%.

Gelonghui, July 7 — Innovation-driven pharmaceutical stocks, which had been rising consistently, saw a collective pullback today, with the sector index declining by more than 3%. Among constituent stocks, Hainan Pharmaceutical hit the daily trading limit down at the open, while Angli Kang and Kelun Pharmaceutical fell by over 8%. Shijiazhuang Pharma Jingfeng, Shuanglu Pharmaceutical, Shanghai Yizhong, SYHA Therapeutics Co., Ltd., Weikang Pharmaceutical, BeiGene Tianheng, Sunshine Lake Pharma, and RemeGen all dropped by more than 7%, while Xinli Tai and Changshan Pharmaceutical declined by over 5%. According to analysis from Kouzi, an AI-powered financial investment assistant app, today’s decline in the innovative drug sector is likely attributable to profit-taking following a recent sharp rally and capital reallocation. (1) Excessive short-term gains triggered concentrated profit-taking: From June 18 to July 6, the innovative drug sector...

Gelonghui FinanceJul 7 11:01

Pharmaceutical stocks are seeing a wave of share buybacks, with E Fund's low-fee Hong Kong Stock Connect Innovative Drug ETF (159316) rising over 4%, and gaining more than 16% over the past five trading days.

Gelonghui, July 3 | The Hong Kong-listed innovative drug sector rose, with Hansoh Pharmaceutical, Luye Pharma, CSPC Pharma, BeiGene, Ascentage Pharma, Akeso, and Livzon Pharmaceutical all gaining over 4%, driving the E Fund CSI HK Connect Innovative Drug ETF (159316) up more than 4%. The ETF has surged over 16% in the past five trading days. On the news front, a wave of share buybacks is sweeping through pharmaceutical stocks, signaling emerging opportunities at the industry’s cyclical bottom: From April 1 to June 21 this year, a total of 68 A-share pharmaceutical companies implemented share repurchases amounting to RMB 3.8 billion, a 54.1% increase compared to the first quarter (RMB 2.466 billion). During this period, over 70 companies announced share repurchase proposals, compared to the first quarter (

Gelonghui FinanceJul 3 10:11

The Day of Approval, the Moment of Bottoming: Baili Tianheng Ushers in a Valuation Rebound for Innovative Drugs

In June 2026, the A-share pharmaceutical sector remains mired in difficulties. The CSI All Share Pharmaceutical Index has plummeted from its peak of over 17,700 points on February 2021 to around the 7,000-point level—a decline of more than 60%—with over 80% of individual stocks underperforming the broader market. Across the Pacific, however, the scene is markedly different. The U.S.-listed biotech ETF XBI has recently entered a strong uptrend, hitting a new 52-week high as of June 30, with a year-to-date gain of 29.92%, firmly trading above its 200-day moving average. On one side stands a powerful rally reaching 52-week highs; on the other, valuations in the A-share pharma space have sunk to a decade-long low. This extreme divergence points to a central question: as global capital re-prices biotech assets, which players in the A-share market will break through first?

Gelonghui FinanceJul 2 16:45

Baili Tianheng (688506.SH): Repurchased a cumulative total of 763,600 shares of the company's stock

Gelonghui, July 2 — BeiLi TianHeng (688506.SH) announced that, as of June 30, 2026, the company has cumulatively repurchased 763,600 of its shares through the centralized bidding trading system of the Shanghai Stock Exchange, representing 0.18% of the company's total share capital. The highest repurchase price was RMB 268.88 per share, and the lowest was RMB 201.02 per share, with a total amount paid of RMB 169.9198 million (excluding stamp duty, trading commissions, and other transaction fees).

Gelonghui FinanceJul 2 16:38

557 pharmaceutical products pass initial review, intensifying the battle for 2026 health insurance coverage

Guancha SyndicateJun 30 14:57